Practice Matters
Managing Drug Interactions With Oral Anticancer Treatments
Lisa K. Lohr, PharmD, Kimball T. Blake, BS, Cindy M. Chan, BS, Sabrina Sturm, PharmD, and Gavyn T. Walsh, BA
From M Health/Fairview Pharmacy Services, Minneapolis, Minnesota
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Lisa K. Lohr, PharmD,
M Health/Fairview, 909 Fulton Street SE,
Minneapolis, MN 55455
E-mail: lisa.lohr@fairview.org
J Adv Pract Oncol 2023;14(5):419–438 |
https://doi.org/10.6004/jadpro.2023.14.5.7 |
© 2023 Harborside™
ABSTRACT
The use of oral anticancer treatments is widespread and vital to modern cancer treatment. Novel oral chemotherapy and targeted therapy treatments continue to receive US Food and Drug Administration approval every year, making knowledge of these agents a necessity for practitioners working in oncology. Many oral anticancer agents are prone to drug interactions that can contribute to adverse effects and decrease therapy efficacy. Potential drug-drug interactions include (1) interactions with CYP3A4 inhibitors and inducers, (2) interactions related to gastric acid suppression, (3) interactions related to prolongation of the cardiac QT interval, (4) interactions related to anticoagulant medications, and (5) drug-food and drug-herb interactions. Identifying potential drug interactions and appropriately managing them is key to preventing adverse effects and ensuring maximum efficacy while on oral anticancer therapy. Management of adverse effects increases patient compliance, ensures medication safety, and allows patients to remain on therapy. This article discusses the mechanisms of interactions and types of interacting medications. Specific recommendations are discussed.
For access to the full length article, please
sign in.
